An announcement from Amarin (AMRN) is now available.
Patrick Holt has stepped down as President and CEO of Amarin Corporation plc, with Aaron Berg succeeding him in the role and joining the company’s board. Berg brings a wealth of experience from his previous leadership roles in the pharmaceutical industry, including a strong background in marketing and sales. Meanwhile, the company faces a challenge as a significant pharmacy benefit manager plans to remove VASCEPA from its Commercial national formularies, which currently accounts for about a quarter of the product’s U.S. prescription volume, although Medicare Part D coverage remains unaffected.
For detailed information about AMRN stock, go to TipRanks’ Stock Analysis page.
